In breast cancer, cyclin E2 shows a greater prognostic value, including being part of gene signatures that predict disease progression in metastatic breast cancer, whereas cyclin E1 is absent from these same signatures [15,16]. The gene discussed is CCNE2; the disease is breast carcinoma.